Analyst Naureen Quibria from Capital One Financial reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price target at $26.00. Naureen Quibria has given his
Analyst Naureen Quibria from Capital One Financial reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price target at $26.00. Naureen Quibria has given his
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate
Even with a brief drop this week, the markets are showing strength this year, with the S&P 500 climbing 8%. However, there’s a big question on investors’ minds: Can this momentum
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to two new employees to purchase
Goldman Sachs initiated coverage of Olema Oncology with a Buy rating and $24 price target. The company’s lead asset, palazestrant is being developed for advanced/metastatic ER+/HER2- breast cancer with total